Published in Mov Disord on September 15, 2007
Imaging Studies of Cognitive Impairment in Parkinson s Disease | NCT01862744
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology (2009) 3.65
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 2.50
REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci (2010) 2.46
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int (2010) 2.27
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord (2011) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Longitudinal study of normal cognition in Parkinson disease. Neurology (2015) 1.59
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology (2016) 1.51
Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord (2008) 1.49
CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology (2015) 1.45
Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology (2015) 1.45
Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology (2015) 1.43
Cognitive rehabiliation for Parkinson's disease demantia: a study protocol for a pilot randomised controlled trial. Trials (2016) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res (2016) 1.40
Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov Disord (2008) 1.40
Plasma α-synuclein predicts cognitive decline in Parkinson's disease. J Neurol Neurosurg Psychiatry (2017) 1.39
The diagnosis of young-onset dementia. Lancet Neurol (2010) 1.37
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology (2012) 1.33
Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med (2012) 1.30
Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci (2013) 1.27
Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 1.27
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Front Syst Neurosci (2013) 1.22
Decision-making cognition in neurodegenerative diseases. Nat Rev Neurol (2010) 1.20
Mild cognitive impairment in Parkinson's disease. Minerva Med (2011) 1.19
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol (2012) 1.17
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord (2010) 1.13
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis (2013) 1.12
Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology (2012) 1.11
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One (2013) 1.10
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology (2011) 1.09
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol (2009) 1.05
Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging (2009) 1.04
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology (2012) 1.04
Visual spatial cognition in neurodegenerative disease. Neurocase (2010) 1.03
Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord (2010) 1.03
Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int (2013) 1.01
Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS One (2013) 1.01
Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am J Pathol (2009) 1.00
Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.99
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. Neurol Genet (2016) 0.98
Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord (2010) 0.98
Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol (2012) 0.98
Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord (2014) 0.98
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry (2010) 0.98
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol (2012) 0.98
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology (2012) 0.95
Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem (2009) 0.95
Profile of cognitive impairment in Parkinson's disease. Brain Pathol (2010) 0.95
Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging (2012) 0.94
Impaired financial abilities in Parkinson's disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord (2013) 0.93
Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord (2014) 0.93
Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) (2014) 0.92
Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener (2013) 0.92
Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol (2012) 0.92
Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neurol (2008) 0.92
Psychiatric issues in cognitive impairment. Mov Disord (2014) 0.91
Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons Dis (2011) 0.91
Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. J Neural Transm (Vienna) (2013) 0.91
Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain (2013) 0.90
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.90
Clock drawing in the Montreal Cognitive Assessment: recommendations for dementia assessment. Dement Geriatr Cogn Disord (2011) 0.90
Anatomical correlates of cognitive functions in early Parkinson's disease patients. PLoS One (2013) 0.90
Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. J Parkinsons Dis (2014) 0.90
IMPROVING THE CLINICAL DETECTION OF LEWY BODY DEMENTIA WITH THE LEWY BODY COMPOSITE RISK SCORE. Alzheimers Dement (Amst) (2015) 0.89
Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis (2012) 0.89
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther (2014) 0.89
Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol (2014) 0.89
Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol (2014) 0.89
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord (2011) 0.88
Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease. Neuroimage (2014) 0.88
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med (2012) 5.64
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Alzheimer's disease. Lancet (2011) 5.35
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (2011) 4.37
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns (2002) 4.30
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet (2013) 3.64
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Early consolidation in human primary motor cortex. Nature (2002) 3.56
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res (2002) 3.22
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol (2005) 3.10
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07